NEONeoGenomics, Inc.
Price
+92%1YEnd-of-day closes, not the intraday tick.
A mixed picture: the questions disagree
Quality mixed, a flag to check, growing in the filings, the market undecided.
NeoGenomics, Inc., a Nevada corporation (referred to individually as the “Company” or collectively with its subsidiaries as “NeoGenomics,” “we,” “us,” or “our” in this Annual Report on Form 10-K) is the registrant for SEC reporting purposes.
In the company’s own words · 10-K filed Feb 17, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
NeoGenomics, Inc. (NEO) reported revenue of $202M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 46% and net income of $2.2M (1.1% of revenue). For the full year FY2025, revenue was $727M (+10% year on year) and net income −$108M. Its largest product in Q2 2026 was Client Direct Billing at $138M, 68% of the disclosed total, well ahead of Commercial Insurance at 18%. The next results filing is expected around Jan 11, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026CEO Transition On September 30, 2026, the Board of Directors (the “Board”) of the Company approved the appointment of Warren Stone, the Company’s current President and Chief Operating Officer, as Chief Executive Officer of the Company and a member of the Board, effective as of January 4, 2027.Earnings release · Form 8-K
- Aug 11, 2026On August 11, 2026, NeoGenomics, Inc. (the “Company”) announced that Alicia Olivo, EVP, General Counsel & Business Development, would transition from her role with the Company and cease to serve as General Counsel effective as of September 21, 2026.Director or officer change · Form 8-K
- Jul 28, 2026NeoGenomics Reports Second Quarter 2026 Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $201.7MThe company’s own SEC segment disclosure.
- Client Direct Billing$138.0M68%
- Commercial Insurance$36.3M18%
- Medicare And Other Governmental$27.4M14%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #16 of 21 by RyuScore